Israel has closed its newest investigation into Canadian allegations of dumping of cannabis into the Israeli market from Canada, citing human error.
Israel’s Commissioner for Trade Levies and the Ministry of Economy and Industry have quietly closed their new investigation into allegations of dumping of medical cannabis into the Israeli market from Canada.
In an internal memo, the Investigating Manager of Anti-dumping and Safeguard measures with the Ministry of Economy and Industry said the termination of the investigation, launched in late June, was due to an error in failing to submit it to Canada’s own regulatory authority beforehand (in this case, Global Affairs Canada, the federal department that manages Canada’s diplomatic relations, international trade, and consular services).
The investigation can still be reopened, though, if it meets the requirements, the Ministry of Economy and Industry told Israel’s Cannabis Magazine, the first to cover the story.
The internal memo reads:
“Further to the Commissioner’s notice dated June 29, 2026, regarding the initiation of an anti-dumping investigation into imports of cannabis from Canada following a complaint filed, the Trade Remedies Commissioner has decided to terminate the aforementioned investigation on procedural grounds only, due to a human error as a result of which notice of the initiation of the investigation was not submitted to the competent authority of the exporting country prior to initiating the investigation.
“This decision is not based on any substantive determination regarding the merits of the complaint.
“For the avoidance of doubt, it is hereby clarified that this notice is issued without prejudice to any rights, claims, causes of action, or remedies available to any of the parties, including the right to file an additional complaint or initiate a new investigation on this matter.” (h/t Deepak Anand).
In an email from Global Affairs Canada, the agency reiterates that the investigation was pulled due to “human error” and cautions that it can still be relaunched.
“While this is welcome news, please note that it remains possible that a new or updated complaint could be filed, or a new investigation initiated,” reads the email. “We therefore recommend that implicated Canadian companies continue to advance their efforts to be prepared for an investigation, should it be re-initiated.”
Israeli cannabis producers have been lobbying their government for several years to address what many say is the unloading of low-cost cannabis for the country’s medical market by Canadian producers. An initial investigation began in November 2024, during which the Commissioner for Trade Levies said they found evidence of dumping that caused material harm to the local industry and recommended that steep tariffs, as high as 165%, be applied to certain Canadian cannabis companies.
While the Advisory Committee recommended adopting these findings in March 2025, the Minister of Finance opposed tariffs or levies, and the issue was eventually dropped until a new investigation was announced in June 2026.
Canadian companies have exported 33,640 kg of cannabis worth about $23.1 million to Israel in the first five months of 2026 and 40,203 kg in 2025.
Although Israel is consistently one of the top 10 export countries for Canadian cannabis, this represents just 7% of the 485,625 kg of cannabis exported from Canada in the first five months of 2026 and 14% of the total for all of 2025.
Countries like Germany, Portugal and Australia receive the majority of these exports. By comparison, Germany imported 176.1 million kilograms of cannabis for medical purposes from Canada in the first five months of 2026.
